Triple artemisinin-containing combination anti-malarial treatments should be implemented now to delay the emergence of resistance

Abstract Resistance threatens all our currently available anti-malarial drugs. Triple artemisinin-containing combination anti-malarial treatments (TACTs) combine an artemisinin derivative with two slowly eliminated partner drugs. TACTs are undergoing large-scale trials. If they prove safe, well-tole...

Full description

Bibliographic Details
Published in:Malaria Journal
Main Author: Nicholas J. White
Format: Article in Journal/Newspaper
Language:English
Published: BMC 2019
Subjects:
Arctic medicine. Tropical medicine
RC955-962
Infectious and parasitic diseases
RC109-216
Arctic
Online Access:https://doi.org/10.1186/s12936-019-2955-z
https://doaj.org/article/ec9725f0916a4bf89289216756e3f4b5
Description
Summary:Abstract Resistance threatens all our currently available anti-malarial drugs. Triple artemisinin-containing combination anti-malarial treatments (TACTs) combine an artemisinin derivative with two slowly eliminated partner drugs. TACTs are undergoing large-scale trials. If they prove safe, well-tolerated and efficacious then they should be deployed. This is in order to protect and extend the useful therapeutic life of the current generation of anti-malarial drugs, which are so essential for malaria control and elimination.

Similar Items